Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Dransfield (Birmingham, United States of America), C. Crim (Research Triangle Park, United States of America), G. Criner (Philadelphia, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Stockley Park West, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lipson (King of Prussia, United States of America), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), R. Wise (Baltimore, United States of America). Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT. 1991

Member's Comments

No comment yet.

Related content which might interest you: The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Evaluation of adherence of patients with asthma to treatment by single combination inhaler Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes Source: International Congress 2017 – COPD management Year: 2017 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations? Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Treatment patterns in English asthma patients initiating multiple inhaler triple therapy: a cohort study Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses Source: International Congress 2017 – COPD management Year: 2017 Influence of treatment by single combined inhaler on adherence of patients with asthma Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Asthma patients‘ preferences for single inhaler therapy Source: Eur Respir J 2004; 24: Suppl. 48, 285s Year: 2004 Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013